Bill Maher

GLP-1 is a peptide.

You make these things naturally, but these can be synthesized and put into the body, and they can have an effect.

And typically, when a drug, like a GLP-1 drug, like Ozempic, Munjaro, or the big one that's coming, this is going to be a trillion-dollar drug, and it has huge implications for the sorts of things you and I think about, the interaction between politics and health.

is retatrutide.

It's a GLP-3, meaning it hits the GLP receptor, GIP, and glucagon.

It can cause up to a third of loss in body weight and some degree of muscle sparing, some.

People should still exercise.

Now, Eli Lilly holds the patent.

It went through phase three very successfully.

Eli Lilly does not want compounding pharmacies selling Reta-Trutide.

Why?

Because it's far cheaper.

And we had this recent thing where Trump argued for lower drug prices, right?

Yeah.

Do you think the drug companies were like, oh yeah, sure, let's just lower drug prices?

No.

It was a deal.

I won't say how I know this, but it was a deal whereby the administration kind of did a wink nod that drugs are going to pass more quickly through R&D to market.

So they're going to make up the cost differential on the research and development end.

Less money invested in research and development, less time to market, and happy to lower prices.